ATE231396T1 - Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht - Google Patents

Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht

Info

Publication number
ATE231396T1
ATE231396T1 AT95901509T AT95901509T ATE231396T1 AT E231396 T1 ATE231396 T1 AT E231396T1 AT 95901509 T AT95901509 T AT 95901509T AT 95901509 T AT95901509 T AT 95901509T AT E231396 T1 ATE231396 T1 AT E231396T1
Authority
AT
Austria
Prior art keywords
permeability
blood
brain barrier
tyrosine phosphorylation
modulate
Prior art date
Application number
AT95901509T
Other languages
English (en)
Inventor
James Martin Staddon
Lee Lawrence Rubin
Kurt Herrenknecht
Mary Louise Morgan
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE231396T1 publication Critical patent/ATE231396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95901509T 1993-11-19 1994-11-18 Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht ATE231396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323884A GB9323884D0 (en) 1993-11-19 1993-11-19 Physiological modulation
PCT/GB1994/002543 WO1995013820A1 (en) 1993-11-19 1994-11-18 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier

Publications (1)

Publication Number Publication Date
ATE231396T1 true ATE231396T1 (de) 2003-02-15

Family

ID=10745427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901509T ATE231396T1 (de) 1993-11-19 1994-11-18 Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht

Country Status (7)

Country Link
US (2) US6312686B1 (de)
EP (1) EP0728009B1 (de)
JP (1) JPH09505076A (de)
AT (1) ATE231396T1 (de)
DE (1) DE69432055T2 (de)
GB (1) GB9323884D0 (de)
WO (1) WO1995013820A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423372D0 (en) 1994-11-18 1995-01-11 Eisai London Res Lab Ltd Proteins and their uses
GB9525703D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Screening method
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
AU3378599A (en) * 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6574501B2 (en) * 1998-07-13 2003-06-03 Childrens Hospital Los Angeles Assessing blood brain barrier dynamics or identifying or measuring selected substances or toxins in a subject by analyzing Raman spectrum signals of selected regions in the eye
US7398119B2 (en) * 1998-07-13 2008-07-08 Childrens Hospital Los Angeles Assessing blood brain barrier dynamics or identifying or measuring selected substances, including ethanol or toxins, in a subject by analyzing Raman spectrum signals
JP2002532720A (ja) * 1998-12-11 2002-10-02 エーザイ株式会社 血管内皮成長因子（ｖｅｇｆ）の使用
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6841351B2 (en) * 1999-07-30 2005-01-11 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6924109B2 (en) * 1999-07-30 2005-08-02 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6961599B2 (en) * 2001-01-09 2005-11-01 Childrens Hospital Los Angeles Identifying or measuring selected substances or toxins in a subject using resonant raman signals
CA2439630A1 (en) * 2001-03-23 2002-10-03 Agy Therapeutics Use of biomolecular targets in the treatment and visualization of brain tumors
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
WO2002094989A2 (en) * 2001-05-18 2002-11-28 The Scripps Research Institute Retroviral vectors and methods of using same
GB2396106B (en) * 2002-12-12 2006-11-15 Johnson & Johnson Medical Ltd Wound dressings comprising enzyme inhibitors
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
US20110064671A1 (en) * 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
US20130079682A1 (en) * 2011-09-25 2013-03-28 David J. Mischelevich Ultrasound-neuromodulation techniques for control of permeability of the blood-brain barrier
US20130224110A1 (en) * 2010-09-16 2013-08-29 Cornell University Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
CN109432410A (zh) * 2018-12-19 2019-03-08 上海康孕企业管理合伙企业（有限合伙） 血红素在预防和/或改善高原反应的药物、食品及保健食品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494175A4 (en) 1989-09-27 1993-05-05 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
JPH0413631A (ja) 1990-04-27 1992-01-17 Tonen Corp アナカルジウム・オクシデンタレ由来の物質
US5155031A (en) 1990-06-07 1992-10-13 Posner Barry I Use of pervanadate as an inhibitor of phosphotyrosine phosphatase

Also Published As

Publication number Publication date
US20020032151A1 (en) 2002-03-14
WO1995013820A1 (en) 1995-05-26
EP0728009A1 (de) 1996-08-28
EP0728009B1 (de) 2003-01-22
DE69432055D1 (de) 2003-02-27
DE69432055T2 (de) 2003-11-06
GB9323884D0 (en) 1994-01-05
JPH09505076A (ja) 1997-05-20
US6312686B1 (en) 2001-11-06

Similar Documents

Publication Publication Date Title
ATE231396T1 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
DE3674642D1 (de) Zur modifizierung von bitumen verwendbare polymerzusammensetzungen und so modifizierte bitumenmassen.
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
DE3762480D1 (de) Mittel zur applikation von transdermal resorbierbaren wirkstoffen.
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
ATE176589T1 (de) Kosmetische und dermatologische zubereitungen mit einem gehalt an delta-aminolävulinsäure
ATE269711T1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
DE3751527D1 (de) Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.
DE3676601D1 (de) Mittel zur injektion von aktiviertem vitamin-d3.
ATE240731T1 (de) Verwendung von levobupivacaine in der pediatrischen chirurgie
DE59610633D1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
DE3671365D1 (de) Topische anwendung des 3-phenylacetylamino-2,6-piperidindions zur behandlung von hautfalten und hyperpigmentierung.
ATE258797T1 (de) Verwendung von amifostin
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
ATE79255T1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties